These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

386 related items for PubMed ID: 15570081

  • 21. Treatment effects of methylphenidate on cognitive functioning in children with mental retardation and ADHD.
    Pearson DA, Santos CW, Casat CD, Lane DM, Jerger SW, Roache JD, Loveland KA, Lachar D, Faria LP, Payne CD, Cleveland LA.
    J Am Acad Child Adolesc Psychiatry; 2004 Jun; 43(6):677-85. PubMed ID: 15167084
    [Abstract] [Full Text] [Related]

  • 22. Equivalent effects of stimulant treatment for attention-deficit hyperactivity disorder during childhood and adolescence.
    Smith BH, Pelham WE, Gnagy E, Yudell RS.
    J Am Acad Child Adolesc Psychiatry; 1998 Mar; 37(3):314-21. PubMed ID: 9519637
    [Abstract] [Full Text] [Related]

  • 23. A randomized, controlled effectiveness trial of OROS-methylphenidate compared to usual care with immediate-release methylphenidate in attention deficit-hyperactivity disorder.
    Steele M, Weiss M, Swanson J, Wang J, Prinzo RS, Binder CE.
    Can J Clin Pharmacol; 2006 Mar; 13(1):e50-62. PubMed ID: 16456216
    [Abstract] [Full Text] [Related]

  • 24. Predicting methylphenidate response in long-term survivors of childhood cancer: a randomized, double-blind, placebo-controlled, crossover trial.
    Conklin HM, Helton S, Ashford J, Mulhern RK, Reddick WE, Brown R, Bonner M, Jasper BW, Wu S, Xiong X, Khan RB.
    J Pediatr Psychol; 2010 Mar; 35(2):144-55. PubMed ID: 19465537
    [Abstract] [Full Text] [Related]

  • 25. A process for developing community consensus regarding the diagnosis and management of attention-deficit/hyperactivity disorder.
    Foy JM, Earls MF.
    Pediatrics; 2005 Jan; 115(1):e97-104. PubMed ID: 15629972
    [Abstract] [Full Text] [Related]

  • 26. Executive impairment determines ADHD medication response: implications for academic achievement.
    Hale JB, Reddy LA, Semrud-Clikeman M, Hain LA, Whitaker J, Morley J, Lawrence K, Smith A, Jones N.
    J Learn Disabil; 2011 Jan; 44(2):196-212. PubMed ID: 21383110
    [Abstract] [Full Text] [Related]

  • 27. Developmental aspects of psychostimulant treatment in children and adolescents with attention-deficit/hyperactivity disorder.
    Findling RL, Short EJ, Manos MJ.
    J Am Acad Child Adolesc Psychiatry; 2001 Dec; 40(12):1441-7. PubMed ID: 11765290
    [Abstract] [Full Text] [Related]

  • 28. Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.
    Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK.
    Clin Ther; 2007 Jun; 29(6):1168-77. PubMed ID: 17692731
    [Abstract] [Full Text] [Related]

  • 29. Treatment effects of methylphenidate on behavioral adjustment in children with mental retardation and ADHD.
    Pearson DA, Santos CW, Roache JD, Casat CD, Loveland KA, Lachar D, Lane DM, Faria LP, Cleveland LA.
    J Am Acad Child Adolesc Psychiatry; 2003 Feb; 42(2):209-16. PubMed ID: 12544181
    [Abstract] [Full Text] [Related]

  • 30. Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study.
    Biederman J, Swanson JM, Wigal SB, Kratochvil CJ, Boellner SW, Earl CQ, Jiang J, Greenhill L.
    Pediatrics; 2005 Dec; 116(6):e777-84. PubMed ID: 16322134
    [Abstract] [Full Text] [Related]

  • 31. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo.
    Levin FR, Evans SM, Brooks DJ, Garawi F.
    Drug Alcohol Depend; 2007 Feb 23; 87(1):20-9. PubMed ID: 16930863
    [Abstract] [Full Text] [Related]

  • 32. Multisite controlled study of OROS methylphenidate in the treatment of adolescents with attention-deficit/hyperactivity disorder.
    Wilens TE, McBurnett K, Bukstein O, McGough J, Greenhill L, Lerner M, Stein MA, Conners CK, Duby J, Newcorn J, Bailey CE, Kratochvil CJ, Coury D, Casat C, Denisco MJ, Halstead P, Bloom L, Zimmerman BA, Gu J, Cooper KM, Lynch JM.
    Arch Pediatr Adolesc Med; 2006 Jan 23; 160(1):82-90. PubMed ID: 16389216
    [Abstract] [Full Text] [Related]

  • 33. Long-term effects of short-acting methylphenidate on growth rates of children with attention deficit hyperactivity disorder at Queen Sirikit National Institute of Child Health.
    Moungnoi P, Maipang P.
    J Med Assoc Thai; 2011 Aug 23; 94 Suppl 3():S158-63. PubMed ID: 22043770
    [Abstract] [Full Text] [Related]

  • 34. Open-label use of placebos in the treatment of ADHD: a pilot study.
    Sandler AD, Bodfish JW.
    Child Care Health Dev; 2008 Jan 23; 34(1):104-10. PubMed ID: 18171451
    [Abstract] [Full Text] [Related]

  • 35. Efficacy and tolerability of OROS methylphenidate in Korean children with attention-deficit/hyperactivity disorder.
    Lee SI, Hong SD, Kim SY, Kim EJ, Kim JH, Kim JH, Park MK, Park S, Park JH, Oh EY, Lim TS, Cheong S, Cho IH, Choi JW.
    Prog Neuropsychopharmacol Biol Psychiatry; 2007 Jan 30; 31(1):210-6. PubMed ID: 17046131
    [Abstract] [Full Text] [Related]

  • 36. Better efficacy for the osmotic release oral system methylphenidate among poor adherents to immediate-release methylphenidate in the three ADHD subtypes.
    Chou WJ, Chou MC, Tzang RF, Hsu YC, Gau SS, Chen SJ, Wu YY, Huang YF, Liang HY, Cheng H.
    Psychiatry Clin Neurosci; 2009 Apr 30; 63(2):167-75. PubMed ID: 19335386
    [Abstract] [Full Text] [Related]

  • 37. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder.
    Spencer T, Biederman J, Wilens T, Doyle R, Surman C, Prince J, Mick E, Aleardi M, Herzig K, Faraone S.
    Biol Psychiatry; 2005 Mar 01; 57(5):456-63. PubMed ID: 15737659
    [Abstract] [Full Text] [Related]

  • 38. A double-blind, placebo-controlled study of modified-release methylphenidate in children with attention-deficit/hyperactivity disorder.
    Greenhill LL, Findling RL, Swanson JM, ADHD Study Group.
    Pediatrics; 2002 Mar 01; 109(3):E39. PubMed ID: 11875167
    [Abstract] [Full Text] [Related]

  • 39. Neurocognitive effects of switching from methylphenidate-IR to OROS-methylphenidate in children with ADHD.
    Kim Y, Shin MS, Kim JW, Yoo HJ, Cho SC, Kim BN.
    Hum Psychopharmacol; 2009 Mar 01; 24(2):95-102. PubMed ID: 19226534
    [Abstract] [Full Text] [Related]

  • 40. Effects of methylphenidate on quality of life in children with both developmental coordination disorder and ADHD.
    Flapper BC, Schoemaker MM.
    Dev Med Child Neurol; 2008 Apr 01; 50(4):294-9. PubMed ID: 18352997
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 20.